Sorting Evidence From Enthusiasm for Depression, Anxiety, OCD, ADHD, and Self-Criticism

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Few off-label medications generate as many questions in an integrative practice as low-dose naltrexone (LDN). Increasingly, those questions come not from people with fibromyalgia or autoimmune disease, but from clients asking whether LDN can help with depression, anxiety, obsessive-compulsive symptoms, attention problems, or even a harsh inner critic. The honest answer is layered, and it deserves to be stated plainly before the enthusiasm runs ahead of the data.

Here is the bottom line up front: LDN has emerging—but still preliminary—evidence and meaningful clinical experience supporting its use as an adjunct for depression and, more tentatively, anxiety—especially when neuroinflammation, chronic pain, or immune dysregulation are part of the picture. For OCD, ADHD, and traits such as self-criticism, the evidence is thin to nonexistent, and any use is frankly experimental. LDN is not a stand-alone psychiatric treatment, and it should never displace first-line, evidence-based care.

Why the mechanism is at least plausible

LDN is not a low dose of an antidepressant; it is a fundamentally different pharmacology from standard naltrexone. At the 1.5–4.5 mg doses used off-label—roughly one-tenth of the 50 mg dose approved for alcohol and opioid use disorder—naltrexone produces only a brief opioid-receptor blockade lasting a few hours. That transient blockade is thought to trigger a compensatory rebound in endogenous opioid (endorphin and enkephalin) signaling and to engage the opioid growth factor axis.

The mechanism most relevant to psychiatry, however, is non-opioid. LDN appears to antagonize Toll-like receptor 4 (TLR4) on microglia and astrocytes—the central nervous system's resident immune cells—dampening release of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 (Younger, Parkitny, and McLain, 2014). This matters because a substantial body of work links neuroinflammation and cytokine activity to depressive symptoms, fatigue, and cognitive fog. A drug that quiets maladaptive glial activation is therefore biologically reasonable to study in mood and anxiety syndromes, particularly where inflammation or central sensitization is suspected. Proposed dopaminergic modulation and speculative effects on BDNF round out the rationale—but those remain theoretical and should be presented as such.

Depression: the strongest—still preliminary—signal

Depression has the most direct evidence of any psychiatric indication, though “most” should not be mistaken for “robust.” The clearest data point is a randomized, placebo-controlled proof-of-concept trial from the Massachusetts General Hospital depression program (Mischoulon et al., 2017). Twelve adults with recurrent major depression experiencing breakthrough symptoms on pro-dopaminergic antidepressant regimens were randomized to LDN 1 mg twice daily or placebo for three weeks. Depression scores improved more in the LDN group, with a moderate effect size (Cohen's d ≈ 0.62), but the difference between groups did not reach statistical significance (p = 0.3)—an outcome entirely expected in a sample that small. It is best read as a promising, underpowered signal rather than a positive trial.

More recently, a larger randomized, double-blind, placebo-controlled trial evaluated adjunctive LDN at 4.5 mg daily over roughly 12 weeks, incorporating high-sensitivity CRP to probe the inflammatory hypothesis. It is the largest controlled study of LDN for major depression to date, yet it too was limited in its power to detect small effects—reinforcing the theme that the depression literature is suggestive but not yet definitive. Supporting evidence comes indirectly from fibromyalgia research: in a small placebo-controlled crossover trial, LDN improved not only pain but also mood and general life satisfaction (Younger et al., 2013), which is clinically relevant given how often pain and depression travel together.

Practical read: for a client with inflammation-associated or treatment-resistant depression—particularly alongside chronic pain or autoimmune disease—LDN is a reasonable adjunct to consider after, not instead of, established options. Some clients report improvements in mood, energy, or cognitive fog within one to two weeks, but that timeline is anecdotal and variable, and a fair trial generally runs 8–12 weeks.

Anxiety: biologically plausible, clinically investigational

The same glial and endorphin pathways invoked for depression could plausibly support anxiolytic effects, and clinicians do report symptomatic improvement in a subset of anxious clients—most often when there is comorbid chronic pain or immune dysregulation. But there are essentially no rigorous, anxiety-specific randomized trials of LDN. The available signal is mechanistic and observational, not trial-grade. Anxiety should therefore be framed as an investigational target: worth discussing in the right context, but not evidence-based standard of care, and not a substitute for psychotherapy or established pharmacotherapy.

OCD and body-focused behaviors: the weakest extrapolation

This is where careful framing matters most, because the popular rationale is shakier than it sounds. The argument for LDN in OCD borrows from standard-dose naltrexone (around 50 mg) studied in impulse-control and behavioral-addiction contexts—gambling, kleptomania, and body-focused repetitive behaviors such as hair-pulling and skin-picking. Two problems undercut the extrapolation.

• The controlled data are mixed to negative. The best-designed trial in trichotillomania (Grant et al., 2014) randomized 51 adults and failed to show a significant reduction in hair-pulling versus placebo. Cognitive flexibility improved, and a subgroup with a family history of addiction showed a non-significant numerical trend—interesting, but far from confirmation of benefit.
• It is the wrong dose and arguably the wrong condition. Those studies used standard 50 mg naltrexone, not LDN, and body-focused repetitive behaviors are not the same as OCD proper, which has been studied even less. Extending negative, standard-dose impulse-control data to low-dose treatment of OCD is a long inferential leap.

The honest conclusion: LDN for OCD is speculative and off-label at best, supported by scattered reports and clinical anecdote rather than controlled evidence. First-line OCD care—SSRIs at adequate doses and exposure-based therapy—remains the standard.

Self-criticism: not a defined drug target

Self-criticism is a cognitive style and emotional pattern, not a diagnosis, and it has never been studied as an LDN endpoint. Any improvement would be indirect—downstream of better mood, lower anxiety, or improved emotional regulation. There is no literature identifying self-criticism as a specific target for LDN, so expectations here should be modest and explicitly exploratory. This is a domain where psychotherapy—cognitive-behavioral and compassion-focused approaches in particular—has far more to offer than any medication.

ADHD: essentially no controlled evidence

I could not identify controlled studies of LDN for ADHD, and ADHD does not appear among the conditions for which LDN has emerging evidence. Any use in ADHD would be highly experimental. The evidence-based mainstays—stimulants, non-stimulant medications, and behavioral interventions—remain exactly that, and LDN should not be positioned as an alternative to them.

Practical clinical considerations

Because LDN is off-label for every indication above, the most defensible approach is to use it as an adjunct in carefully selected clients—typically those with treatment-resistant mood or anxiety symptoms and a suspected neuroinflammatory or autoimmune contribution—under explicit informed consent and close monitoring.

• Dosing. Psychiatric use mirrors other LDN protocols: commonly 0.5–4.5 mg at bedtime, titrated to tolerability and response. Some clients do better with morning or divided dosing, especially if dreams disrupt sleep. LDN is prepared by compounding pharmacies, since commercial tablets are far higher strength.
• Side effects. Generally mild and transient—most commonly vivid dreams, insomnia, mild gastrointestinal upset, and headache—often easing within the first week or two. Serious adverse events are rare at these doses.
• The interaction that matters. LDN antagonizes opioid receptors, so it can blunt opioid analgesics or precipitate withdrawal in opioid-dependent individuals. It should be paused before planned procedures requiring opioid pain control, and every treating clinician should know the client is taking it.
• Antidepressant compatibility. There is no recognized major pharmacologic interaction between LDN and SSRIs or SNRIs, and it is frequently used alongside them as an adjunct. Standard monitoring still applies.
• Cautions. Hepatic metabolism warrants care in significant liver disease; pregnancy and lactation data are insufficient. Long-term safety data remain limited, as most trials run only weeks to months.

The honest bottom line

LDN is a low-cost, generally well-tolerated option with a coherent anti-inflammatory rationale, which makes it an attractive adjunct to consider—but the strength of the evidence falls off sharply as you move across indications. The case is most reasonable for inflammation-associated or treatment-resistant depression, especially with comorbid pain or immune dysregulation; weaker but mechanistically plausible for anxiety; and genuinely speculative for OCD, self-criticism, and ADHD. Used as part of shared, fully informed decision-making—and never as a replacement for first-line psychiatric care—LDN can have a legitimate place in an integrative plan. Sold as a cure for any of these conditions, it overpromises. Keeping those two framings distinct is the whole job.

References

1.  Mischoulon D, Hylek L, Yeung AS, et al. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. J Affect Disord. 2017;208:6–14. doi:10.1016/j.jad.2016.08.029. (PMID 27736689)

2.  Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. doi:10.1007/s10067-014-2517-2.

3.  Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663–672. doi:10.1111/j.1526-4637.2009.00613.x.

4.  Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–538. doi:10.1002/art.37734.

5.  Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines. 2017;5(2):16. doi:10.3390/biomedicines5020016.

6.  Grant JE, Odlaug BL, Schreiber LR, Kim SW. The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2014;34(1):134–138. doi:10.1097/JCP.0000000000000037. (PMID 24145220)

All references above were verified against PubMed/source journals prior to publication.

About Dr. Kim

Yoon Hang Kim, MD, MPH is a board-certified Preventive Medicine physician with more than 20 years of experience in integrative and functional medicine. He completed his fellowship at the University of Arizona Andrew Weil Center for Integrative Medicine and holds certifications in medical acupuncture, integrative medicine, and holistic medicine. His clinical focus includes low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of three books and more than 20 articles.

Professional: www.yoonhangkim.com    |    Clinical: Direct Integrative Care